Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8345375 | 1.00 | NAAA (0.54) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL583269 | 1.00 | NAAA (0.54) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL21000274 | 0.88 | CTSL (0.44) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL17597799 | 0.86 | NAAA (0.48) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL21570682 | 0.85 | CTSL (0.47) | NAAACTSLCTSBCTSKOPRM1 | |
| Ammonia Solution, Strong SCHEMBL8053075 | 0.84 | NAAA (0.47) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL27571563 | 0.84 | CTSL (0.41) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL22762091 | 0.84 | OPRM1 (0.49) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL17103670 | 0.84 | OPRM1 (0.49) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL17103669 | 0.84 | OPRM1 (0.49) | CTSLCTSBCTSKOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689879-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-02-12 | — | — | EP | disclosed |
| CN-111148746-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-08-05 | — | — | CN | disclosed |
| US-11274101-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11242348-B2 | — | — | 2022-02-08 | — | — | US | disclosed |
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-13 | — | — | US | disclosed |
| EP-3689879-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-08-05 | — | — | EP | disclosed |
| CN-111148746-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-05-12 | — | — | CN | disclosed |
| US-6001841-A | ANTISENSE DIAGNOSTICS, THERAPEUTICS AND RESEARCH REAGENTS. | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0689460-A1 | CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| US-5359044-A | Diagnosis, chemical intermediates | ISIS PHARMACEUTICALS (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994019023-A1 | CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | NAAA 1344/4885CTSL 257/4885CTSB 584/4885 |
| US-11274101-B2 | Heterocyclic compound | MAG, HTT, ACHE | NAAA 1344/4885CTSL 257/4885CTSB 584/4885 |
| US-11242348-B2 | — | MAG, ACHE, GAP43 | NAAA 1549/4885CTSL 93/4885CTSB 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.